Anti-malignin antibody in serum and other tumor marker determinations in breast cancer.
In this study, 154 healthy volunteers and 76 patients were tested using the anti-malignin antibody in serum (AMAS) test. Of the 154 volunteers, three were AMAS positive. After further examination, two were positive for cancer and one had a history of ulcerative colitis. Tumor biopsies of 43 suspicious mammography patients revealed that 32 were cancerous and 11 were benign by pathology. For the cancer patients, 31/32 were positive for the AMAS test, while 4/11 of the pathological benign cases were AMAS positive. In comparison to cancer antigen tests, AMAS was more sensitive (97%) in detecting breast cancer than CEA (0%), CA 15-3 (10%), CA 19-5 (5%) or CA 125 (16%) in the same patients.
Thornthwaite
J T
JT
Cancer Research Institute of West Tennessee, Henderson, TN 38340, USA. jtt@aenear.net
D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D001706:Biopsy; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000601:surgery; D002272:Carcinoembryonic Antigen / Q000097:blood; D002278:Carcinoma in Situ / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D005069:Evaluation Studies as Topic; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D008297:Male; D008327:Mammography; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000276:immunology*; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000912:Antibodies, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D009363:Neoplasm Proteins; C016548:malignin